Request An Appointment
Phone

Approved Oncology Drugs

As a result of our clinical research program, we are proud to be a part of the FDA approval of the following oncology/hematology drugs.

2017

  • Pertuzumab – (PERJETA); Genentech, Inc.; for treatment of HER2-positive early breast cancer. Approved December 2017
  • Nivolumab – (OPDIVO); Bristol-Myers Squibb; for treatment of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. Approved December 2017
  • Bosutinib – (BOSULIF); Pfizer Inc.; for treatment of newly-diagnosed chronic phase, Philadelphia chromosome positive, chronic myelogenous leukemia (CML). Approved December 2017
  • Cabozantinib – (Cabometyx); Exelixis, Inc.; for treatment of advanced renal cell carcinoma (RCC). Approved December 2017.
  • Ogivri – (trastuzumab-dkst); Mylan; for the treatment of  HER2-overexpressing breast or metastatic stomach cancer Approved December 2017
  • FoundationOne CDx – (F1CDx); Foundation Medicine, Inc.; in vitro diagnostic to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. Approved November 2017
  • Sunitinib Malate – (Sutent); Pfizer Inc.; for treatment of recurrent renal cell carcinoma following nephrectomy. Approved November 2017
  • Obinutuzumab – (GAZYVA); Genentech, Inc.; for the treatment previously untreated stage II bulky, III, or IV follicular lymphoma. Approved November 2017
  • Brentuximab Vedotin – (ADCETRIS); Seattle Genetics, Inc.; for treatment of primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides. Approved November 2017.
  • Alectinib – (ALECENSA); Hoffmann-La Roche, Inc./Genentech, Inc.; for treatment of anaplastic lymphoma kinase positive metastatic non-small cell lung cancer. Approved November 2017
  • Acalabrutinib – (Calquence); AstraZeneca Pharmaceuticals Inc. under license of Acerta Pharma BV; for treatment of mantle cell lymphoma Approved October 2017
  • Axicabtagene Ciloleucel – (YESCARTA); Kite Pharma, Inc.; for treatment relapsed or refractory large B-cell lymphoma. Approved October 2017
  • Abemaciclib – (VERZENIO); Eli Lilly and Company;for treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.  Approved September 2017
  • Nivolumab – (OPDIVO); Bristol-Myers Squibb Co.; for the treatment of hepatocellular carcinoma. Approved September 2017
  • Pembrolizumab – (KEYTRUDA); Merck & Co., Inc.; for treatment of locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma Approved September 2017
  • Cabazitaxel – (JEVTANA); Sanofi-Aventisin; for treatment metastatic castration-resistant prostate cancer. Approved September 2017
  • Copanlisib – (ALIQOPA); Bayer HealthCare Pharmaceuticals Inc.; for  treatment of relapsed follicular lymphoma. Approved September 2017
  • Mvasi (bevacizumab-awwb); Amgen Inc.; for treatment of cancer. Approved September 2017
  • Gemtuzumab Ozogamicin – (Mylotarg); Pfizer Inc.; for treatment of newly-diagnosed CD33-positive acute myeloid leukemia and relapsed or refractory CD33-positive AML Approved September2017
  • Tisagenlecleucel – (KYMRIAH); Novartis Pharmaceuticals Corp.; for treatment B-cell precursor acute lymphoblastic leukemia. Approved August 2017
  • Olaparib tablets (Lynparza); AstraZenecafor; for treatment recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Approved  August 2017
  • Inotuzumab Ozogamicin – (BESPONSA); Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.; for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia Approved August 2017
  • Liposome-encapsulated combination of Daunorubicin and Cytarabine – (VYXEOS); Jazz Pharmaceuticals, Inc.; for treatment of newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes. Approved August 2017
  • Ibrutinib – (Imbruvica); Pharmacyclics LLC; for treatment of chronic graft versus host disease. Approved  August 2017
  • Enasidenib – (IDHIFA); Celgene Corp.; for treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2. Approved August 2017
  • Nivolumab – (OPDIVO); Bristol-Myers Squibb Company; for treatment of mismatch repair deficient and microsatellite instability high metastatic colorectal cancer. Approved August 2017
  • Neratinib – (NERLYNX); Puma Biotechnology, Inc.; for treatment of early stage HER2-overexpressed/amplified breast cancer. Approved July 2017
  • Blinatumomab – (BLINCYTO); Amgen Inc.; for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approved July 2017
  • Praxis Extended RAS Panel – Illumina, Inc.; a next generation sequencing test to detect certain genetic mutations in RAS genes in tumor samples of patients with metastatic colorectal cancer. Appproved June 2017
  • Betrixaban – (BEVYXXA); Portolafor; the prophylaxis of venous thromboembolism. Approved June 2017
  • Dabrafenib and Trametinib – (TAFINLAR and MEKINIST); Novartis Pharmaceuticals Inc.; for treatment of metastatic non-small cell lung cancer with BRAF V600E mutation. Approved June 2017
  • Rituximab and Hyaluronidase – (RITUXAN HYCELA); Genentech Inc.; for treatment of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Approved June 2017
  • Ceritinib – (ZYKADIA); Novartis Pharmaceuticals Corp.; for treatment of metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase positive. Approved May 2017
  • Pembrolizumab – (KEYTRUDA); Merck & Co.; for treatment of unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors. Approved May 2017
  • Pembrolizumab – (KEYTRUDA); Merck and Co., Inc.; for treatment of locally advanced or metastatic urothelial carcinoma. Approved May 2017
  • Pembrolizumab – (KEYTRUDA); Merck and Co., Inc.; for treatment of metastatic non-squamous non-small  cell lung cancer. Approved May 2017
  • Avelumab – (BAVENCIO); EMD Serono, Inc.; for treatment of locally advanced or metastatic urothelial carcinoma. Approved May 2017
  • Durvalumab – (IMFINZI); AstraZeneca UK Limited; for treatment of locally advanced or metastatic urothelial carcinoma. Approved May 2017
  • Brigatinib (ALUNBRIG); Takeda Pharmaceutical Company Limited, through its wholly owned subsidiary ARIAD Pharmaceuticals, Inc.; for treatment of metastatic anaplastic lymphoma kinase positive non-small cell lung cancer. Approved April 2017
  • Midostaurin – (RYDAPT); Novartis Pharmaceuticals Corp.; for treatment of newly diagnosed acute myeloid leukemia who are FLT3 mutation-positive. Approved April 2017
  • Regorafenib – (STIVARGA); Bayer HealthCare Pharmaceuticals Inc; for treatment of hepatocellular carcinoma. Approved April 2017
  • Philips IntelliSite Pathology Solution (PIPS); Philips Medical Systems Nederland B.V.; as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded. Approved April 2017
  • Ipsogen JAK2 RGQ PCR Kit – QIAGEN GmbH.; to detect mutations affecting the Janus Tyrosine Kinase 2 gene. Approved March 2017
  • Palbociclib – (IBRANCE); Pfizer Inc.; for treatment of hormone receptor positive human epidermal growth factor receptor 2  negative advanced or metastatic breast cancer. Approved March 2017
  • Osimertinib – (TAGRISSO); AstraZeneca Pharmaceuticals, LP; for treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. Approved  March 2017
  • Niraparib – (ZEJULA); Tesaro, Inc.; for treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Approved March 2017
  • Avelumab – (BAVENCIO); EMD Serono, Inc.; for treatment of metastatic Merkel cell carcinoma. Approved March 2017
  • Pembrolizumab – (KEYTRUDA); Merck and Co., Inc.; for treatment of refractory classical Hodgkin lymphoma or those who have relapsed after three or more prior lines of therapy. Approved March 2017
  • Ribociclib – (KISQALI); Novartis Pharmaceuticals Corp.; for treatment of postmenopausal hormone receptor positive human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer. Approved March 2017
  • Lenalidomide – (Revlimid); Celgene Corp.;  for treatment of multiple myeloma following autologous stem cell transplant. Approved February 2017
  • Nivolumab – (OPDIVO); Bristol-Myers Squibb Company; for treatment of locally advanced or metastatic urothelial carcinoma. Approved February 2017

2016

  • Rubraca – (rucaparib); Clovis Oncology; For the treatment of women with a certain type of ovarian cancer
  • Lartruvo – (olaratumab); Eli Lilly; For the treatment of adults with certain types of soft tissue sarcoma
  • Tecentriq – (atezolizumab); Genentech; For the treatment of urothelial carcinoma, the most common type of bladder cancer
  • Venclexta – (venetoclax); Abbvie and Genetech; For the treatment of chronic lymphocytic leukemia in patients with a specific chromosomal abnormality

2015

  • Cotellic – (cobimetinib); Genentech; For the treatment of BRAF V600E or V600K melanoma, Approved November 2015
  • Darzalex- (daratumumab); Janssen Biotech; For the treatment of multiple myeloma, Approved November 2015
  • Imlygic – (talimogene laherparepvec); Amgen; For the treatment of unresectable recurrent melanoma, Approved October 2015
  • Lonsurf – (trifluridine and tipiracil); Taiho Oncology; For the treatment of metastatic colorectal cancer , Approved September 2015
  • Opdivo – (nivolumab); Bristol-Myers Squibb; For the treatment of metastatic squamous non-small cell lung cancer, Approved March 2015

2014

  • Azynzeo – (netupitant and palonosetron);Helsinn; For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014
  • Imbruvica – (ibrutunib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014
  • Lynparza – (olaparib); AstraZeneca; For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014
  • Opdivo – (nivolumab); Bristol-Myers Squibb; For the treatment of unresectable or metastatic melanoma, Approved December 2014
  • Zydelig – (idelalisib);Gilead; For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma, Approved July 2014

2013

  • Gilotrif – (afatinib); Boehringer Ingelheim; For the treatment of metastatic non-small cell lung cancer with EGFR mutations
  • Imbruvica – (ibrutinib);Pharmacyclics; For the treatment of mantle cell lymphoma, Approved November of 2013
  • Pomalyst – (pomalidomide); Celgene; For the treatment of relapsed and refractory multiple myeloma
  • Stivarga – (regorafenib); Bayer; For the treatment of gastrointestinal stromal tumor

2012

  • Subsys – (fentanyl sublingual spray); Insys Therapeutics; For the treatment of breakthrough cancer pain
  • Pertuzumab – (perjeta); Roche; For the treatment of HER2-positive metastatic breast cancer
  • Carfilzomib – (kyprolis); Onyx Pharmaceuticals; For the treatment of multiple myeloma
  • Ziv-aflibercept – (zaltrap); Sanofi; For the treatment of metastatic colorectal cancer

2011

  • Lazanda – (fentanyl citrate) nasal spray; Archimedes; For the management of breakthrough cancer pain
  • Zytiga – (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer

2010

  • Halaven – (eribulin mesylate); Eisai; For the treatment of metastatic breast cancer
  • Jevtana – (cabazitaxel) ; Sanofi Aventis; For the treatment of prostate cancer

2009

  • Onsolis – (fentanyl buccal); BioDelivery Sciences; For the management of breakthrough cancer pain
  • Afinitor – (everolimus); Novartis; For the treatment of renal cell carcinoma
  • Folotyn– (pralatrexate injection); Allos Therapeutics; For the treatment of peripheral T-cell lymphoma

2008

  • Sancuso – (granisetron); ProStrakan; For the treatment of chemotherapy-induced nausea and vomiting

2006

  • Sutent– (sunitinib); Pfizer; For the treatment of kidney cancer and gastrointestinal stromal tumors

2005

  • Nexavar – (sorafenib); Bayer/Onyx; For the treatment of Renal Cell Carcinoma

 

Return to Clinical Trials